RxDoctor Payments Data

Dmitry Khaitov, MD

Neurology · Allentown, PANPI 1720249048

Payments from drug & device makers

$70,363in general payments, 2019–2025

Across 69 payments — averaging $1019.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$43K
  • Sanofi$16K
  • Novartis$9K
  • Genentech, Inc.$2K
  • EMD Serono, Inc.$362
  • Amgen$111
  • plus $15 from 1 others
$14,395in research payments, 2019–2025

Across 8 payments — averaging $1799.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$14K

What the payments were for

  • Consulting fees$11,60325%
  • Speaking & faculty fees$30,74467%
  • Travel & lodging$1,8304%
  • Food & beverage$1,6264%
  • Education$540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen40$43,005
Sanofi1$16,000
Novartis10$9,335
Genentech, Inc.2$1,535
EMD Serono, Inc.10$362
Amgen5$111
TG Therapeutics, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,363 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$51,472
Medicare patients
352
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate59$410,876
EnspryngSatralizumab-Mwge11$204,050
Avonex (4 Pack)Interferon Beta-1a21$165,225
AubagioTeriflunomide13$113,718
AustedoDeutetrabenazine12$71,349
Teriflunomide22$39,777
Dalfampridine ErDalfampridine16$20,815
Emgality PenGalcanezumab-Gnlm12$14,512
Nurtec OdtRimegepant Sulfate13$12,576
Carbidopa-LevodopaCarbidopa/Levodopa203$8,932
Primidone51$3,207
Carbidopa-Levodopa ErCarbidopa/Levodopa38$2,881
Gabapentin149$2,851
Donepezil Hcl249$2,827
Baclofen118$2,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$43,005$165,22521 claims
SanofiAubagio$16,000$113,71813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →